Wang Daoxi,Li Lang,Jiang Jun,et al.Research advances on etiology and treatment of pediatric osteoporosis[J].Journal of Clinical Pediatric Surgery,,22():689-693.[doi:10.3760/cma.j.cn101785-202303050-016]
Research advances on etiology and treatment of pediatric osteoporosis
- Keywords:
- Osteoporosis; Surgical Procedures; Operative; Child
- Abstract:
- Affecting the skeletal development of children and adolescents, pediatric osteoporosis is one of the common causes leading to severe morbidity and reduced quality-of-life in children.Osteoporosis has a complex etiology and it may be divided into secondary and primary types.Secondary osteoporosis is more common with causes including long-term use of glucocorticoids, malignancies, cerebral palsy, muscular dystrophy and systemic lupus erythematosus.Primary osteoporosis is mostly rare, including osteogenesis imperfecta, idiopathic juvenile osteoporosis, cystinuria and Marfan’s syndrome.The characteristic of osteoporosis is frequent spontaneous fractures.In growing children, their skeletons have great potential for recovery and remodeling.Thus an early detection of osteoporosis may prevent fractures, improve bone deformities, preserve joint function and enhance mobility.The aim of this article is to review the research progress on the etiology and treatment of osteoporosis in children.
References:
[1] El-Gazzar A, H?gler W.Mechanisms of bone fragility:from osteogenesis imperfecta to secondary osteoporosis[J].Int J Mol Sci, 2021, 22(2):625.DOI:10.3390/ijms22020625.
[2] Ciancia S, van Rijn RR, H?gler W, et al.Osteoporosis in children and adolescents:when to suspect and how to diagnose it[J].Eur J Pediatr, 2022, 181(7):2549-2561.DOI:10.1007/s00431-022-04455-2.
[3] Jang MJ, Shin C, Kim S, et al.Factors affecting bone mineral density in children and adolescents with secondary osteoporosis[J].Ann Pediatr Endocrinol Metab, 2023, 28(1):34-41.DOI:10.6065/apem.2244026.013.
[4] Li XF, Cui LK, Chen WH, et al.QiangGuYin modulates the OPG/RANKL/RANK pathway by increasing secretin levels during treatment of primary type I osteoporosis[J].Evid Based Complement Alternat Med, 2021, 2021:7114139.DOI:10.1155/2021/7114139.
[5] Matsumoto T, Endo I.RANKL as a target for the treatment of osteoporosis[J].J Bone Miner Metab, 2021, 39(1):91-105.DOI:10.1007/s00774-020-01153-7.
[6] Zou BH, Zheng JH, Deng WD, et al.Kirenol inhibits RANKL-induced osteoclastogenesis and prevents ovariectomized-induced osteoporosis via suppressing the Ca2+-NFATc1 and Cav-1 signaling pathways[J].Phytomedicine, 2021, 80:153377.DOI:10.1016/j.phymed.2020.153377.
[7] Bae S, Kim K, Kang K, et al.RANKL-responsive epigenetic me-chanism reprograms macrophages into bone-resorbing osteoclasts[J].Cell Mol Immunol, 2023, 20(1):94-109.DOI:10.1038/s41423-022-00959-x.
[8] Berkün O, F?nd?k Y, Akp?nar O, et al.Evaluation of RANK, RANKL and OPG levels in gingival crevicular fluid after surgically assisted rapid maxillary expansion[J].J Maxillofac Oral Surg, 2022, 21(2):487-492.DOI:10.1007/s12663-020-01481-1.
[9] Laine CM, Koltin D, Susic M, et al.Primary osteoporosis without features of OI in children and adolescents:clinical and genetic characteristics[J].Am J Med Genet A, 2012, 158A(6):1252-1261.DOI:10.1002/ajmg.a.35278.
[10] Laine CM, Laine T.Diagnosis of osteoporosis in children and adolescents[J].Eur Endocrinol, 2013, 9(2):141-144.DOI:10.17925/EE.2013.09.02.141.
[11] Engelke K, Lang T, Khosla S, et al.Clinical use of quantitative computed tomography (QCT) of the hip in the management of osteoporosis in adults:the 2015 ISCD official positions-part I[J].J Clin Densitom, 2015, 18(3):338-358.DOI:10.1016/j.jocd.2015.06.012.
[12] Bishop N, Arundel P, Clark E, et al.Fracture prediction and the definition of osteoporosis in children and adolescents:the ISCD 2013 Pediatric Official Positions[J].J Clin Densitom, 2014, 17(2):275-280.DOI:10.1016/j.jocd.2014.01.004.
[13] 郑荣飞, 熊丰.儿童骨质疏松症诊疗进展[J].中国实用儿科杂志, 2016, 31(3):227-232.DOI:10.7504/ek2016030617. Zheng RF, Xiong F.Advance in the diagnosis and treatment of osteoporosis in children[J].Chin J Pract Pediatr, 2016, 31(3):227-232.DOI:10.7504/ek2016030617.
[14] Bai ZM, Wang JG, Kang MM, et al.Effects of pamidronate disodium combined with calcium on BMD values and severity of pain in elderly patients with osteoporosis based on mobile terminal platform for Internet of things[J].Dis Markers, 2022, 2022:5069918.DOI:10.1155/2022/5069918.
[15] Golding PH.Dual-energy X-ray absorptiometry (DXA) to measure bone mineral density (BMD) for diagnosis of osteoporosis-experimental data from artificial vertebrae confirms significant dependence on bone size[J].Bone Rep, 2022, 17:101607.DOI:10.1016/j.bonr.2022.101607.
[16] Agarwal S, Shane E, Lang T, et al.Spine volumetric BMD and strength in premenopausal idiopathic osteoporosis:effect of teriparatide followed by denosumab[J].J Clin Endocrinol Metab, 2022, 107(7):e2690-e2701.DOI:10.1210/clinem/dgac232.
[17] Shevroja E, Cafarelli FP, Guglielmi G, et al.DXA parameters, Trabecular Bone Score (TBS) and Bone Mineral Density (BMD), in fracture risk prediction in endocrine-mediated secondary osteoporosis[J].Endocrine, 2021, 74(1):20-28.DOI:10.1007/s12020-021-02806-x.
[18] Tan ZJ, Shek HT, Dong ZX, et al.Retrospective analyses of clinical features in 28 Chinese patients with type V osteogenesis imperfecta:new perspectives in an old issue[J].Osteoporos Int, 2023, 34(2):369-377.DOI:10.1007/s00198-022-06581-x.
[19] 王广, 林涨源, 卢邦宝, 等.儿童成骨不全症1例报告及文献综述[J].临床小儿外科杂志, 2023, 22(1):84-87.DOI:10.3760/cma.j.cn101785-202209010-016. Wang G, Lin ZY, Lu BB, et al.Osteogenesis imperfect:one case report with a literature review[J].J Clin Ped Sur, 2023, 22(1):84-87.DOI:10.3760/cma.j.cn101785-202209010-016.
[20] Dabas A, Malhotra R, Kumar R, et al.Idiopathic juvenile osteoporosis in a child:a four-year follow-up with review of literature[J].J Pediatr Endocrinol Metab, 2021, 34(11):1487-1490.DOI:10.1515/jpem-2021-0233.
[21] Janicka-Szczepaniak M, Orczyk K, Szymbor K, et al.Is it possible to predict a risk of osteoporosis in patients with juvenile idiopathic arthritis? A study of serum levels of bone turnover markers[J].Acta Biochim Pol, 2018, 65(2):297-302.DOI:10.18388/abp.2017_2561.
[22] 马燕华, 王覃, 李静, 等.特发性青少年骨质疏松症研究进展[J].中国骨质疏松杂志, 2022, 28(6):916-921.DOI:10.3969/j.issn.1006-7108.2022.06.024. Ma YH, Wang Q, Li J, et al.Research progress in idiopathic juvenile osteoporosis[J].Chin J Osteopor, 2022, 28(6):916-921.DOI:10.3969/j.issn.1006-7108.2022.06.024.
[23] 王立, 苏喆, 焦燕华.儿童骨质疏松症的诊治[J].中国实用儿科杂志, 2022, 37(8):595-600.DOI:10.19538/j.ek2022080607. Wang L, Su Z, Jiao YH.Diagnosis and treatment of osteoporosis in children[J].Chin J Pract Pediatr, 2022, 37(8):595-600.DOI:10.19538/j.ek2022080607.
[24] Saraff V, H?gler W.Endocrinology and adolescence:osteoporosis in children:diagnosis and management[J].Eur J Endocrinol, 2015, 173(6):R185-R197.DOI:10.1530/EJE-14-0865.
[25] Ward LM, Konji VN, Ma J.The management of osteoporosis in children[J].Osteoporos Int, 2016, 27(7):2147-2179.DOI:10.1007/s00198-016-3515-9.
[26] Formosa MM, Bergen DJM, Gregson CL, et al.A roadmap to gene discoveries and novel therapies in monogenic low and high bone mass disorders[J].Front Endocrinol (Lausanne), 2021, 12:709711.DOI:10.3389/fendo.2021.709711.
[27] Li C, Huang Q, Yang R, et al.Targeted next generation sequencing of nine osteoporosis-related genes in the Wnt signaling pathway among Chinese postmenopausal women[J].Endocrine, 2020, 68(3):669-678.DOI:10.1007/s12020-020-02248-x.
[28] Zhao Y, Yan JP, Zhu YM, et al.A novel prognostic 6-gene signature for osteoporosis[J].Front Endocrinol (Lausanne), 2022, 13:968397.DOI:10.3389/fendo.2022.968397.
[29] Hurley T, Zareen Z, Stewart P, et al.Bisphosphonate use in children with cerebral palsy[J].Cochrane Database Syst Rev, 2021, 7(7):CD012756.DOI:10.1002/14651858.CD012756.pub2.
[30] Yamasaki S, Kamezaki K, Ito Y, et al.Bisphosphonate use for glucocorticoid-induced osteoporosis in elderly patients with immune thrombocytopenia receiving prolonged steroid therapy:a single institute retrospective study[J].Hematol Rep, 2022, 14(3):276-285.DOI:10.3390/hematolrep14030039.
[31] Weng BF, Chen CH.Effects of bisphosphonate on osteocyte proliferation and bone formation in patients with diabetic osteoporosis[J].Comput Math Methods Med, 2022, 2022:2368564.DOI:10.1155/2022/2368564.
[32] Xu Q, Zhan P, Li XF, et al.Bisphosphonate-enoxacin inhibit osteoclast formation and function by abrogating RANKL-induced JNK signalling pathways during osteoporosis treatment[J].J Cell Mol Med, 2021, 25(21):10126-10139.DOI:10.1111/jcmm.16949.
[33] Lee H, Lee S, Kim D, et al.Effect of dosing interval on compliance of osteoporosis patients on bisphosphonate therapy:observational study using nationwide insurance claims data[J].J Clin Med, 2021, 10(19):4350.DOI:10.3390/jcm10194350.
[34] Bandeira F, de Oliveira LB, Bilezikian JP.Long-term consequences of osteoporosis therapy with denosumab[J].Arch Endocrinol Metab, 2022, 66(5):717-723.DOI:10.20945/2359-3997000000560.
[35] Li PF, Wu XJ, Li Y, et al.Denosumab versus bisphosphonates for the prevention of the vertebral fractures in men with osteoporosis:an updated network meta-analysis[J].Clin Invest Med, 2022, 45(3):E14-E22.DOI:10.25011/cim.v45i3.38875.
[36] Kong SH.Denosumab, an effective osteoporosis treatment option for men[J].Korean J Intern Med, 2022, 37(5):947-948.DOI:10.3904/kjim.2022.261.
[37] Hoyer-Kuhn H, Rehberg M, Netzer C, et al.Individualized treatment with denosumab in children with osteogenesis imperfecta-follow up of a trial cohort[J].Orphanet J Rare Dis, 2019, 14(1):219.DOI:10.1186/s13023-019-1197-z.
[38] Kobayashi T, Nakamura Y, Suzuki T, et al.Efficacy and safety of denosumab therapy for osteogenesis imperfecta patients with osteoporosis-case series[J].J Clin Med, 2018, 7(12):479.DOI:10.3390/jcm7120479.
[39] Uehara M, Nakamura Y, Takahashi J, et al.Efficacy of denosumab for osteoporosis in three female patients with osteogenesis imperfecta[J].Tohoku J Exp Med, 2017, 242(2):115-120.DOI:10.1620/tjem.242.115.
[40] Hoyer-Kuhn H, Semler O, Schoenau E.Effect of denosumab on the growing skeleton in osteogenesis imperfecta[J].J Clin Endocrinol Metab, 2014, 99(11):3954-3955.DOI:10.1210/jc.2014-3072.
[41] Tamechika SY, Ohmura SI, Maeda S, et al.Efficacy of denosumab on bisphosphonate-treated osteoporosis and osteopenia in systemic rheumatic disease patients receiving glucocorticoids[J].J Bone Miner Metab, 2023, 41(2):203-211.DOI:10.1007/s00774-022-01393-9.
[42] Lei MM, Tavares E, Buzgo E, et al.Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma[J].Leuk Lymphoma, 2022, 63(13):3249-3252.DOI:10.1080/10428194.2022.2115840.
[43] True HD, Ricks RG, Smith JA.Denosumab and bisphosphonate associated bilateral osteonecrosis of the external auditory canal[J].Drug Ther Bull, 2023, 61(4):61-63.DOI:10.1136/dtb.2022.241203rep.
[44] Hoyer-Kuhn H, Franklin J, Allo G, et al.Safety and efficacy of denosumab in children with osteogenesis imperfect——a first prospective trial[J].J Musculoskelet Neuronal Interact, 2016, 16(1):24-32.
[45] Bacchetta J, Boutroy S, Vilayphiou N, et al.Teriparatide therapy and bone mineral accrual in children with idiopathic osteoporosis[J].J Bone Miner Res, 2020, 35(6):1087-1094.DOI:10.1002/jbmr.3982.
[46] Schweizer R, Martin DD, Haase M, et al.Similar effects of long-term exogenous growth hormone (GH) on bone and muscle parameters:a pQCT study of GH-deficient and small-for-gestational-age (SGA) children[J].Bone, 2007, 41(5):875-881.DOI:10.1016/j.bone.2007.06.028.
Memo
收稿日期:2023-03-20。
基金项目:四川省自然科学基金（2022NSFSC1517）
通讯作者:刘利君,Email:ll1964@126.com